Introduction
Randomised controlled trials (RCTs) and meta-analyses have demonstrated that cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in appropriately selected patients with symptomatic heart failure (HF), reduced left ventricular ejection fraction (LVEF) and QRS prolongation on the electrocardiogram.
1 -7 Accordingly, the benefits of CRT for such patients were accorded high levels of evidence and strong recommendations in European Society of Cardiology (ESC) and other international guidelines. 8 -12 The first ESC CRT survey, performed in 2008-2009 in 13 ESC countries, demonstrated that implanters often extrapolated the benefits of CRT to a broader population including patient groups that were not well represented in RCTs, such as patients aged >75 years or with a QRS duration <120 ms, atrial fibrillation (AF), or requiring an upgrade from an existing permanent pacemaker (PPM) or implantable cardioverter defibrillator (ICD). The first CRT survey also showed considerable regional and national differences in implantation practices. 13 Since this survey was published, several important modifications of ESC guideline recommendations concerning CRT indications have been made by both the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA). 8, 9, 12 Therefore, these two ESC Associations decided to collaborate and undertake a pan-European survey designed to describe current clinical practice regarding implantation of CRT devices in a larger sample of patients and greater number of ESC member countries. CRT Survey II was not designed to compare results with the first survey. There was limited overlap between the cohorts of the two surveys and substantial differences in the data collected precluding valid comparison. Lessons learned from conducting the first survey were used to improve both the design and performance of CRT Survey II, which involved many more countries. CRT Survey II provides insights into contemporary clinical practice that is useful for patients, clinicians, administrators, the pharmaceutical and device industry as well as for parties who fund health care. Further analyses confined to the subset of countries participating in both surveys are planned.
. 
Methods

Survey infrastructure
The survey was designed as a joint initiative between the EHRA and HFA. These two ESC Associations co-coordinated the survey with sponsorship from all five companies that manufacture CRT devices as well as from several pharmaceutical and diagnostic companies (see Acknowledgements). The design and rationale of CRT Survey II, along with the detailed contents of the electronic case report form (eCRF) have been published previously. 14 A Scientific Committee was established, composed of equal number of members from each Association, together with non-voting representatives from each of the five CRT device companies. The Scientific Committee regularly monitored the progress of the survey and agreed on logistical adjustments during the period of data collection.
Recruitment
The 47 ESC member states detailed in the 2014 EHRA White Book, which provided information on the number of sites implanting CRT and volume of activity in these countries, were invited to participate. 15 Each participating ESC member country was represented by a National Coordinator who was nominated by the President of their National Cardiology Society. The National Coordinators were responsible for obtaining national Institutional Review Board approval if required, recruiting centres in their country and distributing information from the Scientific Committee to their implanters. Of the 47 invited ESC member countries, 42 agreed to participate. The National Coordinators were requested to contact CRT implanters in their countries and invite them to participate in the survey. Sites were then asked to enter consecutive patients implanted with a CRT during the inclusion period. Overall, 288 individual centres participated in CRT Survey II.
Data collection, management and analyses
For the first ESC CRT survey, the web-based eCRF used for data collection was developed by Institut für Herzinfarktforschung Ludwigshafen (IHF), 16 which also conducted data management and statistical analyses. Therefore, the Associations decided that IHF should support similar functions for CRT Survey II. Together with the Scientific Committee, the IHF revised the eCRF, developed the statistical analysis plan and was responsible for data monitoring and verification. No imputation for missing data was done. All percentages are relative to the total number of patients with available information.
Each participating country had their data-points collected in the eCRF benchmarked against the total cohort. The day-to-day operational running of the survey was conducted by Tessa Baak at Stavanger University Hospital, University of Bergen, Norway.
Survey population
Any patient in the 42 participating countries was eligible for inclusion if he/she was implanted with either a CRT with pacemaker function (CRT-P) or a CRT with an incorporated defibrillator (CRT-D). This included both successful and unsuccessful implantations as well as both de-novo CRT devices and upgrades from a PPM or ICD. Generator replacements or revisions of existing CRT devices were excluded as the survey was designed to capture only new CRT implantations.
The one-time site questionnaire
Each implanting centre was requested to complete a one-time site questionnaire, which provided information on hospital type, size, population served, operator speciality, infrastructure, facilities and implantation routines for their CRT device programme. The data collected also provided useful information related to health care resource utilisation. 14 
The electronic case report form
Implanting centres were asked to complete a web-based eCRF of consecutive patients scheduled to receive a CRT device. The eCRF collected information on patient characteristics, investigations, indications for CRT, implant procedures and short-term outcomes including adverse events and complications during the index hospitalisation. 14 Information on longer-term outcome was not collected. The eCRF was reviewed by ESC data protection consultants to ensure patient anonymity. This, together with the fact that the survey did not include follow-up data after discharge, obviated the necessity for formal Institutional Review Board approval in most countries. Most centres were simply required to notify their local or national ethics committee of their participation in the survey.
Timelines
The first patient was included on 1 October 2015. The survey was initially planned to run for 9 months. However, the Scientific Committee decided to extend the enrolment by 6 months to 31 December 2016 in order to increase sample size and improve representativeness and therefore the ability to compare differences in practice amongst participating countries.
Results
The CRT Survey II recruited 11 088 patients from 42 ESC countries. in Table 1 . Using data from the EHRA White Book 2015 on national implantation rates we estimated representativeness, 17 that is the number of patients enrolled compared with expected total implants in that country. This metric was updated continuously and permitted us to estimate how representative of the predicted national implantation rates was the data collected in the survey.
Overall, the survey collected data on 11% of expected implantations during the enrolment period of the survey. Of the 42 countries, 34 (81%) had >10% of the expected total number of implants for that country.
Tables 2-6 report key findings from the total cohort and the number of patients contributing to each data-point.
Hospital demographics
University hospitals accounted for 59% of participating centres. The median (interquartile range, IQR) number of CRT implants per hospital per year was 52 (30-96) and 76% of centres were participating in a national device registry. Device remote monitoring was employed by 59% of centres and 99% of centres had either partial or total reimbursement from public health providers ( Table 2) .
Patient characteristics
The median (IQR) age at implantation was 70 (62-76) years, 32% of patients were aged ≥75 years and 24% were women. Half of the patients had ischaemic heart disease, 41% had a prior history of AF of which 42% of these were permanent AF, 31% had diabetes mellitus, and 47% had a HF hospitalisation during the previous year ( Table 3) .
Pre-implant clinical evaluation
Most patients were in New York Heart Association (NYHA) functional class III or IV (60%) and the natriuretic peptide levels were generally substantially elevated. The ECG at the time of implantation showed AF in 26%, a QRS duration of <130 ms in 13% and ≥150 ms in 69% of patients and 73% had left bundle branch block (LBBB). On imaging, 13% of patients had an LVEF >35%, the median (IQR) left ventricular end-diastolic diameter was 63 (58-69) mm and 34% had either moderate or severe mitral regurgitation. The clinical indication for CRT implantation was HF with a wide QRS in 60% of cases, HF or left ventricular dysfunction and indication for an ICD in 48%. In 10% of patients the sole clinical indication for CRT was HF and a PPM indication with expected right ventricular pacing dependence ( Table 4) .
Cardiac resynchronisation therapy implant procedure
Hospital admission was elective for 77% of implants, 77% of which were performed by electrophysiologists; 97% of procedures were successful, 70% of devices implanted were CRT-D and only 25% were referrals from other centres. The median (IQR) duration of the procedure was 90 (65-120) min. The right ventricular lead was implanted first in 84% of cases and the left ventricular lead was multipolar in 57%. The left ventricular position was evaluated by biplane X-ray projection in 88% of patients. The left anterior oblique site was lateral in 84% and the right anterior oblique site was middle in 71%. The peri-procedural complication rate was 6%.
The most common complications were coronary sinus dissection, bleeding and pneumothorax ( 
Post-cardiac resynchronisation therapy implant data
The median (IQR) hospital stay was 3 (2-7) days. In 5% of patients an adverse event was reported and 0.4% died during the index hospitalisation. Follow-up was planned at the implanting centre in 86% of patients. Atrio-ventricular programming was performed prior to discharge in 58% and ventriculo-ventricular programming in 56% of patients. Device-based software was used to optimize programming in 36%. HF medications at discharge included loop diuretics (81%), beta-blockers (89%), angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (86%) and mineralocorticoid receptor antagonists (MRAs) (63%). Overall, 47% of patients were anticoagulated, mostly (70%) with warfarin; 10% of anticoagulated patients had no history of AF ( Table 6) . 
Benchmarking the top 10 recruiting countries
Data from the 10 countries that enrolled the most patients were compared. There were substantial differences amongst countries in the mean age of patients implanted ( Figure 1A) . Symptom severity varied substantially amongst countries ( Figure 1B) . The proportion of patients with AF was about 26% with a range of 16 to 29%. In all countries, most patients had LBBB but this ranged from as low as 61% to 82% ( Figure 1C) . The percentage of patients with a QRS duration <130 ms ranged from 7% to 19% but most patients had a QRS duration >150 ms ( Figure 1D) . The percentage of patients upgraded from another device was between 21% and 39% ( Figure 1E ) and those receiving a CRT-P ranged from 2% to 37% ( Figure 1F) . The median duration of hospitalisation varied markedly ( Figure 1G) , with a median of 3 days.
Discussion
This second, larger survey of CRT implantations in ESC member countries provides a valuable source of clinical information describing 'who is doing what to whom and how', permits benchmarking across Europe and provides essential feedback on guideline adherence, which supports the development of future guidelines.
The 'Who' are implanters, and as expected, primarily electrophysiologists, although a considerable number of implanters are not (23%). The 'What' are primarily CRT-D devices (70%) but in many countries up to 40% of implants are CRT-P devices. The 'Whom' (patients selected for CRT implantation) are predominantly men, . . <75 years, with an LVEF <35%, in sinus rhythm, with LBBB and a QRS duration ≥150 ms. The 'How' reveals that most implantations are elective with a low peri-procedural mortality (<1%). Referrals from non-implanting centres accounted for only 25%, indicating that patients outside university or teaching hospital settings have limited access to CRT. The Swedish HF Registry, which included 12 807 patients, demonstrated that underutilisation was associated with demographic, organizational and socio-economic characteristics as well as clinical information. For example, the likelihood of being considered for CRT was much higher if the patients were managed by cardiologists rather than other specialists or primary care physicians.
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An excellent overview of the diverse issues that serve to explain why only about one-third of CRT candidates are actually implanted with a device has recently been published. 19 CRT Survey II also confirms that clinicians continue to extrapolate data from RCTs to patients who are not well represented in the evidence base. Clinical practice may be guided by clinical trials but differences in practice exist because clinicians have accumulated experience and try to offer the best treatment to individual patients, many of whom do not fulfil the selection criteria for the RCTs. Many devices were implanted in patients with AF or relatively narrow QRS complexes, or requiring a device upgrade. In these patient groups, guidelines either contraindicate CRT or make only weak recommendations. Compared to patients enrolled in RCTs, patients in this survey were generally older, had more co-morbidities, were less likely to have ischaemic heart disease, had higher LVEF, narrower QRS complexes and more AF but a similar proportion were women. 20 Compared to men, the low number of women receiving CRT is of concern. Women with HF with reduced ejection fraction (HFrEF) are more likely to have LBBB and may benefit from CRT at a shorter QRS duration than men. 21, 22 However, women with HF are older and less likely to have a reduced LVEF. 23 Accordingly, the low number of women receiving CRT may reflect the relatively lower number of women aged <75 years with HFrEF rather than a lower proportion of such women who are eligible for CRT.
CRT implants were upgrades from a previous PPM or ICD device in 28% of procedures. The landmark trials of CRT, with the exception of RAFT, excluded patients with a prior device. In RAFT, an upgrade from an ICD or PPM was not associated with benefit. 8 Although pacing generally prolongs QRS duration, its clinical significance with respect to CRT may differ. The importance of atrio-ventricular resynchronisation may be as or more important than bi-ventricular resynchronisation and the benefit of upgrading devices to CRT is not well established.
The rhythm at implantation was AF for 26% patients in this survey. The 2013 EHRA and 2012 and 2016 HFA guidelines provide either a IIa or IIb recommendation for patients with AF but emphasise the importance of pharmacological rate control or atrio-ventricular nodal ablation in order to adequately ensure bi-ventricular capture. 8, 9, 12 No substantial trial has compared CRT to a pharmacological control group for patients with AF. A subgroup of patients in the RAFT study had AF and did not appear to benefit, which was ascribed to inadequate ventricular capture. 7 Similarly, a recent report from COMPANION also suggested that patients with a prior history of AF did not benefit from CRT, although incident AF did not appear to reduce benefit in CARE-HF. 4, 24 At least two trials have compared CRT to right ventricular pacing after atrio-ventricular node ablation. These suggest that CRT is superior. 25, 26 However, whether this reflects a benefit from CRT or simply avoiding the harm of right ventricular pacing is unclear. For this reason, some experts think that current guidelines provide an unduly strong recommendation for CRT in patients with AF. This survey shows that 8% of implants were in patients with a QRS <120 ms and that a further 5% had a QRS duration 120-129 ms. The 2012 HFA guidelines recommended CRT implantation only when QRS duration was >120 ms in the presence of more severe symptoms and LBBB or QRS >130 ms when symptoms were mild and LBBB was present or when QRS duration was >150 ms in the absence of LBBB. 12 In May 2016 the most recent version of the HFA guidelines, based on the results of EchoCRT and an individual-patient data meta-analysis, suggested that CRT is contraindicated when QRS duration is <130 ms. 8, 27 -29 This survey ran from October 2015 to December 2016. Future analyses will determine whether practice evolved over the course of the survey. 9, 12 Of note, the median QRS duration was narrower (144 ms compared with 160 ms) for patients implanted only for the clinical indication 'PM indicated and expected right ventricular pacing dependence' compared to the overall cohort. A total of 10% of the survey population were implanted with only this clinical indication and 22% of this group had a QRS duration <120 ms. However, most patients in this survey had a QRS duration ≥150 ms. Individual-patient data meta-analyses of RCTs have convincingly shown that longer QRS durations predict greater long-term benefit from CRT. 28, 30 Patients in this survey were generally treated with loop diuretics (81%), ACE inhibitors/ARBs (86%), beta-blockers (89%), and MRAs (63%) at discharge from hospital. Guidelines recommend implantation of CRT only after patients have been optimally medically managed. Although the proportion of patients in the survey discharged on disease-modifying medications is less than ideal and less than observed in some registries, it is still similar or greater than observed in most of the landmark clinical trials that proved the efficacy of CRT, many other registries or in clinical practice.
18,31
The process of developing evidence-based guidelines includes both adequate evaluation by randomised clinical trials as well as feedback from surveys and registries. Survey and registries demonstrate the degree to which guidelines are adopted in practice. Therefore, the extensive observational data that we have collected highlight which guideline recommendations are or are not being adhered to as well as how physicians extrapolate existing data to clinical challenges they encounter in practice where evidence is lacking. These gaps in evidence are intentionally included in all ESC guidelines in order to identify potentially fruitful area for future research.
The one-time site questionnaire includes information such as total number of beds per hospital, type of hospital, number of CRT devices implanted annually and the number and speciality of implanters, which provides valuable information related to health care resource demands and capacity. A dedicated health care resource utilisation paper will be published.
. The data selected for benchmarking are directly related to patient selection, clinical practice and health care resource utilisation in the top 10 recruiting countries. Benchmarking of these countries in the survey revealed remarkable similarities with regard to patient selection. However, there were also many highly significant differences between countries (Figure 1) , especially the populations aged ≥75 years with QRS <130 ms, NYHA class III or IV as well as choice of device (CRT-P vs. CRT-D).
Particularly striking was the difference in index hospitalisation duration between the top 10 countries. Hospitalisation for implantation of a CRT can facilitate initiation and up-titration of optimal medical therapy, which can prolong hospital stay. Differences in the length of hospital stay depend both on the implanting centre and the collaboration with the outpatient HF services. Some of the observed differences in these countries' CRT implantation practice will be related to the country's economic strength, the proportion of their budget allocated to health care and the demographics of the population. The initial cost of CRT is substantial due to the device itself, the implantation procedure, hospitalisation and follow-up. However, the symptomatic improvement following CRT and the reduction in HF hospitalisation makes it an effective use of resources. Countries with limited financial resources may select patients most likely to respond and also may prefer CRT-P to CRT-D due to the reduced cost. In Europe, physicians may be more willing to extrapolate beyond the existing evidence and guidelines for CRT because the risk of medical litigation is relatively low. Most procedures are funded partly or entirely by public funding and there is limited formal audit of adherence to guidelines.
Limitations
The strength and ability of a survey to address questions are related to the strength of its methodology, its representativeness and size. Although the number of patients enrolled in this survey was large, there were substantial differences amongst countries. Overall, we estimate that about 11% of patients implanted with CRT in participating countries were enrolled in the survey. We cannot assess the degree of selection bias in the choice of enrolled patients. Sites may have been less likely to report unsuccessful implants or cases with a poor outcome, accounting for low complication and mortality rates. The number of implanting sites ranged from 1 to 37. In countries with few participating centres, these centres' practice will have a great impact on the national results.
The eCRF was designed to be as user-friendly as possible in order to maximise the number of patients enrolled. Unavailable patient data could be omitted; the analyses were based on the available data, which explains the variation in the sample size for each data point. Furthermore, the interpretation of questions was up to the discretion of the investigator. Although there was no formal independent monitoring of the data collection, the IHF conducted 'front-end' data check and post database lock quality control analyses designed to prevent incorrect data being analysed. The most recent ESC HF guidelines were released during the enrolment period of the survey. 8 It requires time before new guidelines are adopted into evolving clinical practice. It is difficult to quantify the effect that this had on the selection and enrolment of patients subsequent to the release of the most recent ESC guidelines.
Conclusion
CRT Survey II provides a valuable source of information on contemporary clinical practice with respect to CRT implantation in a large sample of ESC member states. The survey demonstrates important similarities as well as substantial differences in patient selection, implantation procedure and follow-up. The data collected are sufficient to permit meaningful benchmarking between the highest recruiting countries and for assessing guideline adherence and health care resource utilisation. This should assist in educational initiatives and identifying appropriate directions for future research.
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